(Ovarian Cancer) Is Mirvetuximab Soravtansine + Avastin (Bevacizumab) Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
From May 29 to 31, 2020, Lucy Gilbert presented at the ASCO 2020 Virtual Scientific Program the "Efficacy and Safety Results of Anti-Folate Receptor Alpha (FRα) Antibody-Drug Conjugate (ADC) Mirvetuximab Soravtansine Plus Avastin (Bevacizumab) in Platinum-Agnostic Ovarian Cancer Patients in a Phase 1/2 Clinical Trial."
In this Phase 1/2 clinical trial, platinum-agnostic ovarian cancer patients received mirvetuximab soravtansine 6mg/kg + bevacizumab 15mg/kg once daily in 21-day cycles.
In the FORWARD II Phase 1 trial, mirvetuximab soravtansine was confirmed to achieve objective response rates of 24-47% in platinum-sensitive ovarian cancer patients with high FRα expression, and 39-56% in patients with medium-high FRα expression.
Patient characteristics in this trial: median age 60 years (range 44-83); ovarian cancer types included epithelial ovarian cancer (68%), fallopian tube cancer (25%), and primary peritoneal cancer (7%); performance status: ECOG 0 (75%), ECOG 1 (25%); prior treatment: 1 prior treatment (33%), 2 prior treatments (37%), 3 or more prior treatments (30%); prior drug types: platinum-based anticancer drugs (100%), taxane-based anticancer drugs (98%), anti-angiogenic antibody drugs (40%), and PARP inhibitors (32%).
The overall objective response rate was 47% (N=28). In patients with high FRα expression (N=33), the objective response rate was 61%; in platinum-resistant patients, 59%; and in platinum-sensitive patients, 69%.
The most commonly observed adverse events were diarrhea (68%), blurred vision (63%), fatigue (58%), nausea (55%), peripheral neuropathy (43%), and corneal disease (43%). Grade 3-4 adverse events were hypertension (12%), neutropenia (10%), fatigue (5%), dry eye (5%), and ALT increase (5%). Treatment discontinuation due to adverse events occurred in 22% of patients.
Based on the Phase 1/2 trial results, Lucy Gilbert concluded: "Anti-FRα antibody-drug conjugate mirvetuximab soravtansine plus bevacizumab showed a 64% objective response rate in platinum-agnostic ovarian cancer patients, with particularly high antitumor efficacy in patients with high FRα expression, and adverse events remained manageable."
Source: Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer. (2020 ASCO Virtual Scientific Program, Abstract No: 6004)
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4